{'52WeekChange': 0.25629628,
 'SandP52WeekChange': None,
 'address1': '35 Gatehouse Drive, A2',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.71,
 'askSize': 800,
 'averageDailyVolume10Day': 47350,
 'averageVolume': 82476,
 'averageVolume10days': 47350,
 'beta': None,
 'beta3Year': None,
 'bid': 13.5,
 'bidSize': 800,
 'bookValue': 4.231,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 25.25,
 'dayLow': 23.85,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.373,
 'enterpriseToRevenue': 32.773,
 'enterpriseValue': 540857088,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 25.157429,
 'fiftyTwoWeekHigh': 33.5,
 'fiftyTwoWeekLow': 9.9,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10884520,
 'forwardEps': -2.3,
 'forwardPE': -10.795652,
 'fromCurrency': None,
 'fullTimeEmployees': 80,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.41359,
 'heldPercentInstitutions': 0.47667,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/morphictx.com',
 'longBusinessSummary': 'Morphic Holding, Inc., a biopharmaceutical company, '
                        'discovers and develops oral small-molecule integrin '
                        'therapeutics for the treatment of autoimmune, '
                        'cardiovascular, and metabolic diseases, as well as '
                        'fibrosis and cancer. Its lead product candidates in '
                        'clinical development are MORF-720, a selective oral '
                        'av√\x9f6 specific integrin inhibitor for the '
                        'treatment of idiopathic pulmonary fibrosis (IPF) and '
                        'primary sclerosing cholangitis (PSC); and MORF-057, a '
                        'a4√\x9f7 specific integrin inhibitor for the '
                        'treatment of inflammatory bowel disease (IBD). The '
                        'company is also developing MR √\x9f6 #2, a selective '
                        'av√\x9f6 specific integrin inhibitor to treat IPF and '
                        'PSC; and av√\x9f1 integrin for the treatment of '
                        'fibrosis. Morphic Holding, Inc. has a research '
                        'collaboration with Engitix Ltd for the identification '
                        'of Morphic integrin technology amenable targets in '
                        'fibrostenotic IBD; a collaboration agreement with '
                        'Schr√∂dinger, LLC for integrin targets; and a license '
                        "agreement with Children's Medical Center Corporation "
                        'to develop and commercialize products worldwide for '
                        'any therapeutic or diagnostic use in humans and '
                        'veterinary applications. It also has collaboration '
                        'agreements with AbbVie Biotechnology Ltd and Janssen '
                        'Pharmaceuticals, Inc. to discover or develop '
                        'integrin-based therapeutics; and drug discovery '
                        'research collaboration with HitGen Inc. to identify '
                        'small molecule leads against targets specified by the '
                        'company. The company was founded in 2014 and is based '
                        'in Waltham, Massachusetts.',
 'longName': 'Morphic Holding, Inc.',
 'market': 'us_market',
 'marketCap': 760967488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_345057935',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -54874000,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.25,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 996 0955',
 'previousClose': 25.44,
 'priceHint': 2,
 'priceToBook': 5.868589,
 'priceToSalesTrailing12Months': 46.11086,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 25.25,
 'regularMarketDayLow': 23.85,
 'regularMarketOpen': 25.25,
 'regularMarketPreviousClose': 25.44,
 'regularMarketPrice': 25.25,
 'regularMarketVolume': 33539,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 30647100,
 'sharesPercentSharesOut': 0.0321,
 'sharesShort': 982537,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 448351,
 'shortName': 'Morphic Holding, Inc.',
 'shortPercentOfFloat': 0.0838,
 'shortRatio': 6.67,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'MORF',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.367,
 'twoHundredDayAverage': 18.729065,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a1e60ff9-744a-3908-a947-e5d2f0a617cc',
 'volume': 33539,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.morphictx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}